Tim Shannon
General Partner at Canaan Partners
Westport, Connecticut
Writes $250K – $20M checks · typically $10M
About
Physician-turned-investor trained in pulmonary and critical care; former CuraGen CEO Tim Shannon founded and led Arvinas—pioneering targeted protein degradation—and often serves as board chair shaping scientific strategy and development plans.
Tim Shannon @timshannonmd
Intercept's NASH Trial Design Irks Investors http://t.co/GFf6r7VcsO #IBDNews via @IBDinvestors - $ICPT $GILD $PCYC $GEVA - need a big swing
May 20, 2015 · ♥ 2
Tim Shannon @timshannonmd
Canaan Partners: Don’t Overlook Pharma Customers for Digital-Health Products http://t.co/SlEa99bndr via @WSJ -- nice stuff Julie
May 9, 2015 · ♥ 4 · ⇄ 2
Tim Shannon @timshannonmd
Spyryx Biosciences Secures $18 Million in Series A Financing - FierceBiotech: http://t.co/BxOI03PTUf -- Awesome company - important work
May 7, 2015 · ♥ 1 · ⇄ 1
Invests in
BiotechConsumerDeep TechEnterprise SoftwareFintechHardwareHealthtech
Deals · 6
Vivace TherapeuticsBoard seat
via Canaan Partners · filed Mar 2025 · $35M raise
Aer TherapeuticsBoard seat
via Canaan Partners · filed Feb 2025 · $5M raise
visit ww.nextcure.comBoard seat
via Canaan Partners · filed Nov 2018 · $93.4M raise
Arvinas Holding Co. LLCBoard seat
via Canaan Partners · filed Apr 2018 · $55M raise
Spyryx BiosciencesBoard seat
via Canaan Partners · filed Jul 2017 · $5M raise
CytomX TherapeuticsBoard seat
via Canaan Partners · filed Jan 2015 · $30M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Canaan Partners
Network1
Investors connected to Tim in public investor directories — a warm-intro map.